TAIWAN LIPOSOME/S (TLC) Expected to Announce Earnings of -$0.18 Per Share

Wall Street brokerages expect TAIWAN LIPOSOME/S (NASDAQ:TLC) to report ($0.18) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for TAIWAN LIPOSOME/S’s earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.11). The firm is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that TAIWAN LIPOSOME/S will report full year earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.46). For the next year, analysts anticipate that the firm will report earnings of ($0.79) per share, with EPS estimates ranging from ($1.01) to ($0.44). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover TAIWAN LIPOSOME/S.

A number of research firms have commented on TLC. Cantor Fitzgerald began coverage on TAIWAN LIPOSOME/S in a research note on Thursday, December 27th. They set an “overweight” rating and a $11.00 price objective on the stock. Janney Montgomery Scott began coverage on TAIWAN LIPOSOME/S in a research note on Monday, December 17th. They set a “buy” rating on the stock. Laidlaw began coverage on TAIWAN LIPOSOME/S in a research note on Monday, December 17th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, HC Wainwright began coverage on TAIWAN LIPOSOME/S in a research note on Monday, December 17th. They set a “buy” rating and a $9.00 price objective on the stock.



Shares of NASDAQ TLC traded down $0.17 during trading hours on Wednesday, reaching $6.43. 5,870 shares of the stock were exchanged, compared to its average volume of 16,038. The company has a current ratio of 3.19, a quick ratio of 3.19 and a debt-to-equity ratio of 0.83. TAIWAN LIPOSOME/S has a 52 week low of $5.02 and a 52 week high of $11.00.

About TAIWAN LIPOSOME/S

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Further Reading: What is a stock split?

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply